|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...4344454647484950515253...156157» |
- || Orencia (abatacept) / BMS
Enrollment change: ACTION: Long Term Experience With Abatacept in Routine Clinical Practice (clinicaltrials.gov) - Feb 27, 2016
P=N/A, N=2850, Active, not recruiting, Sponsor: Bristol-Myers Squibb
N=2364 --> 2850
- ||| Havrix (hepatitis A vaccine, inactivated) / GSK
Trial completion, Trial primary completion date: Immunogenicity and Safety of Vaccinations in Immunocompromised Persons (clinicaltrials.gov) - Feb 27, 2016
P=N/A, N=645, Completed, Sponsor: University of Zurich
N=2364 --> 2850 Recruiting --> Completed | Trial primary completion date: May 2016 --> Dec 2015
- Enrollment closed: REPLACE-BG: A Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes (clinicaltrials.gov) - Feb 26, 2016
P=N/A, N=225, Active, not recruiting, Sponsor: T1D Exchange Clinic Network Coordinating Center
Recruiting --> Completed | Trial primary completion date: May 2016 --> Dec 2015 Recruiting --> Active, not recruiting
- opicinumab (BIIB033) / Biogen
Enrollment open: Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants (clinicaltrials.gov) - Feb 26, 2016
P1, N=24, Recruiting, Sponsor: Biogen
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem, Sandoz
Enrollment open, Trial initiation date, Trial primary completion date: PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes (clinicaltrials.gov) - Feb 26, 2016
P1, N=40, Recruiting, Sponsor: Gan and Lee Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Dec 2015 | Trial primary completion date: Feb 2016 --> Jun 2016
- New trial: DREAMED: Feasibility Study to Evaluate the Hybrid-Logic Closed Loop System in Type 1 Diabetes (clinicaltrials.gov) - Feb 26, 2016
P=N/A, N=0, Withdrawn, Sponsor: Medtronic
- ||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
New P2 trial, Combination therapy: A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Feb 26, 2016
P2, N=161, Completed, Sponsor: Hoffmann-La Roche
- |||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open, Trial primary completion date: Muscara: Doppler Evaluation in RA Patients After Adalimumab. (clinicaltrials.gov) - Feb 25, 2016
P4, N=120, Recruiting, Sponsor: Ronald van Vollenhoven, prof.
Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Dec 2015 | Trial primary completion date: Feb 2016 --> Jun 2016 Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2015 --> Sep 2016
- Norditropin (somatropin) / Novo Nordisk, Insuman Rapid (recombinant human insulin) / Sanofi
Trial completion, Trial primary completion date: Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. (clinicaltrials.gov) - Feb 25, 2016
P=N/A, N=9, Completed, Sponsor: University of Aarhus
Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2015 --> Sep 2016 Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Sep 2015
- Enbrel (etanercept) / Pfizer, Amgen
Trial primary completion date: Etanercept in Rheumatoid Arthritis and Vascular Inflammation (clinicaltrials.gov) - Feb 24, 2016
P4, N=10, Recruiting, Sponsor: Innovaderm Research Inc.
Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Sep 2015 Trial primary completion date: Nov 2015 --> Nov 2018
- || Enrollment closed: BD FlowSmart (clinicaltrials.gov) - Feb 24, 2016
P=N/A, N=75, Active, not recruiting, Sponsor: Becton, Dickinson and Company
Trial primary completion date: Nov 2015 --> Nov 2018 Recruiting --> Active, not recruiting
- MIKA Diclofenac Spray Gel (diclofenac spraygel) / Nogra Pharma
Trial completion, Trial primary completion date: Adjuvant Treatment of Graves (clinicaltrials.gov) - Feb 24, 2016
P4, N=65, Completed, Sponsor: Mikael Lantz
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: May 2015 --> Feb 2016
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P2 trial, Combination therapy: Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease (clinicaltrials.gov) - Feb 24, 2016
P2, N=50, Recruiting, Sponsor: Helse Fonna
- zoledronic acid / Generic mfg.
Trial primary completion date: AZAR: Zoledronic Acid in Rheumatoid Arthritis (clinicaltrials.gov) - Feb 24, 2016
P3, N=94, Recruiting, Sponsor: Carmen Gómez-Vaquero
Active, not recruiting --> Completed | Trial primary completion date: May 2015 --> Feb 2016 Trial primary completion date: May 2017 --> May 2018
- |||| blisibimod (A-623) / Anthera Pharma
Trial primary completion date: BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration (clinicaltrials.gov) - Feb 24, 2016
P2/3, N=200, Recruiting, Sponsor: Anthera Pharmaceuticals
Trial primary completion date: May 2017 --> May 2018 Trial primary completion date: Dec 2015 --> Dec 2018
- Trial completion, Enrollment change, Trial primary completion date: Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis (clinicaltrials.gov) - Feb 24, 2016
P2, N=13, Completed, Sponsor: University of Jordan
Trial primary completion date: Dec 2015 --> Dec 2018 Active, not recruiting --> Completed | N=30 --> 13 | Trial primary completion date: Oct 2015 --> Feb 2016
- Trial completion: Evaluating Intervention Responsiveness in People With Multiple Sclerosis (clinicaltrials.gov) - Feb 24, 2016
P=N/A, N=60, Completed, Sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Active, not recruiting --> Completed | N=30 --> 13 | Trial primary completion date: Oct 2015 --> Feb 2016 Active, not recruiting --> Completed
- Enrollment closed, Enrollment change: T and B Cell Responses in Autoimmune Diseases (clinicaltrials.gov) - Feb 23, 2016
P=N/A, N=68, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=280 --> 68
- Enrollment closed, Trial primary completion date: Low Level Laser Therapy for Autoimmune Thyroiditis (clinicaltrials.gov) - Feb 23, 2016
P2/3, N=43, Active, not recruiting, Sponsor: University of Sao Paulo General Hospital
Recruiting --> Active, not recruiting | N=280 --> 68 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Nov 2015
- New trial: NUIRA: NFKB1 and IKK Epsilon in Rheumatoid Arthritis (clinicaltrials.gov) - Feb 23, 2016
P=N/A, N=60, Completed, Sponsor: Asociación Científica Latina A.C.
- ||| Tysabri (natalizumab) / Biogen, Royalty
New trial: Clinical Disease Activity With Long Term Natalizumab Treatment (clinicaltrials.gov) - Feb 23, 2016
P=N/A, N=300, Recruiting, Sponsor: Biogen
- || Orencia (abatacept) / BMS
Trial initiation date, Trial primary completion date: Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study (clinicaltrials.gov) - Feb 23, 2016
P=N/A, N=1000, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Nov 2015 Initiation date: Jul 2012 --> Jan 2018 | Trial primary completion date: Jun 2015 --> Dec 2018
- ||||| New P2a trial: TMP001 in Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Feb 22, 2016
P2a, N=55, Recruiting, Sponsor: Dr. Frank Behrens
- |||| Abrilada (adalimumab-afzb) / Pfizer
Trial primary completion date, Combination therapy: A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02). (clinicaltrials.gov) - Feb 21, 2016
P3, N=560, Recruiting, Sponsor: Pfizer
Initiation date: Jul 2012 --> Jan 2018 | Trial primary completion date: Jun 2015 --> Dec 2018 Trial primary completion date: Jan 2017 --> Aug 2016
- Humira (adalimumab) / Eisai, AbbVie
Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date: ORIENT: Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA (clinicaltrials.gov) - Feb 21, 2016
P=N/A, N=0, Withdrawn, Sponsor: AbbVie
Trial primary completion date: Jan 2017 --> Aug 2016 N=100 --> 0 | Initiation date: Nov 2015 --> Feb 2016 | Not yet recruiting --> Withdrawn | Trial primary completion date: Nov 2019 --> Feb 2020
- dimethyl fumarate / Generic mfg.
New trial: DTI: Tecfidera Diffusion Tensor Imaging (clinicaltrials.gov) - Feb 21, 2016
P=N/A, N=115, Enrolling by invitation, Sponsor: University at Buffalo
- ||||||| Trial completion, Enrollment change, Trial primary completion date: IGIV Study for Chronic ITP Patients Ages 3-70 (clinicaltrials.gov) - Feb 21, 2016
P3, N=58, Completed, Sponsor: Grifols Biologicals Inc.
N=100 --> 0 | Initiation date: Nov 2015 --> Feb 2016 | Not yet recruiting --> Withdrawn | Trial primary completion date: Nov 2019 --> Feb 2020 Recruiting --> Completed | N=75 --> 58 | Trial primary completion date: Mar 2017 --> Mar 2012
- Trial completion, HEOR: CSII in Type 1 Diabetes: Diet, Quality of Life & Cardiometabolic Risks - A Cross-Sectional Study (clinicaltrials.gov) - Feb 21, 2016
P=N/A, N=60, Completed, Sponsor: Liverpool John Moores University
Recruiting --> Completed | N=75 --> 58 | Trial primary completion date: Mar 2017 --> Mar 2012 Active, not recruiting --> Completed
- Trial completion, Enrollment change, HEOR: CSII in Type 1 Diabetes: Diet, Quality of Life & Cardiometabolic Risks - A Longitudinal Study (clinicaltrials.gov) - Feb 21, 2016
P=N/A, N=5, Completed, Sponsor: Liverpool John Moores University
Active, not recruiting --> Completed Recruiting --> Completed | N=25 --> 5
- Trial completion, Enrollment change: Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes. (clinicaltrials.gov) - Feb 21, 2016
P=N/A, N=279, Completed, Sponsor: HealthPartners Institute
Recruiting --> Completed | N=25 --> 5 Recruiting --> Completed | N=40 --> 279
- cyclophosphamide / Generic mfg.
Enrollment change: Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus (clinicaltrials.gov) - Feb 18, 2016
P2, N=9, Terminated, Sponsor: New York University School of Medicine
Recruiting --> Completed | N=40 --> 279 N=24 --> 9
- Biomarker, New trial: JAQI: Juvenile Arthritis Quantitative Imaging (clinicaltrials.gov) - Feb 18, 2016
P=N/A, N=200, Recruiting, Sponsor: University College London Hospitals
- New trial: HIFURGD: A Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease (clinicaltrials.gov) - Feb 18, 2016
P=N/A, N=22, Recruiting, Sponsor: The University of Hong Kong
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Phase classification: Anti-CD20 in Systemic Lupus Erythematosus (clinicaltrials.gov) - Feb 18, 2016
P1/2, N=24, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=24 --> 9 Phase classification: P1 --> P1/2
- Trial completion, Trial primary completion date: Effectiveness Registry to Study Therapies for Arthritis and Inflammatory Conditions: The Corrona CERTAIN Sub-study (clinicaltrials.gov) - Feb 18, 2016
P=N/A, N=3000, Completed, Sponsor: The Consortium of Rheumatology Researchers of North America, Inc.
Phase classification: P1 --> P1/2 Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> May 2015
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion, Trial primary completion date, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 18, 2016
P3, N=880, Completed, Sponsor: UCB Pharma SA
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> May 2015 Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Jul 2014
- || atacicept (VT-001) / Vera Therap
Trial primary completion date: Atacicept in Anti-Tumor Necrosis Factor Alpha-na (clinicaltrials.gov) - Feb 17, 2016
P2, N=311, Completed, Sponsor: EMD Serono
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Jul 2014 Trial primary completion date: May 2009 --> Oct 2009
- || Orencia (abatacept) / BMS
Trial primary completion date: Assessment of the Effectiveness of IV and SC Abatacept (Orencia) Patient Alert Cards in Patients With Rheumatoid Arthritis in a Sample of EU Countries (clinicaltrials.gov) - Feb 17, 2016
P=N/A, N=400, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: May 2009 --> Oct 2009 Trial primary completion date: Sep 2016 --> Dec 2016
- | dimethyl fumarate / Generic mfg.
Biomarker, New P4 trial: Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers (clinicaltrials.gov) - Feb 17, 2016
P4, N=20, Recruiting, Sponsor: Multiple Sclerosis Center of Northeastern New York
- || Biomarker, Trial primary completion date: A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome (clinicaltrials.gov) - Feb 17, 2016
P=N/A, N=80, Recruiting, Sponsor: Biogen
Trial primary completion date: Sep 2016 --> Dec 2016 Trial primary completion date: Mar 2017 --> Aug 2017
- New trial: T1 Diabetes Hypoglycemia Prevention Pilot (clinicaltrials.gov) - Feb 17, 2016
P=N/A, N=30, Not yet recruiting, Sponsor: InSpark Technologies, Inc.
- bertilimumab (iCo-008) / iCo Therap, AstraZeneca
Trial primary completion date: Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid (clinicaltrials.gov) - Feb 16, 2016
P2, N=15, Recruiting, Sponsor: Immune Pharmaceuticals
Trial primary completion date: Mar 2017 --> Aug 2017 Trial primary completion date: Feb 2016 --> Dec 2016
- ||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
New P4 trial: Tocilizumab Real-Life Human Factors (RLHFs) Validation Study (clinicaltrials.gov) - Feb 16, 2016
P4, N=95, Not yet recruiting, Sponsor: Hoffmann-La Roche
- Nasulin (intranasal insulin spray) / CPEX
Enrollment change: Intranasal Insulin and Its Effect on Postprandial Metabolism in Comparison to Subcutaneous Insulin (clinicaltrials.gov) - Feb 16, 2016
P2, N=0, Withdrawn, Sponsor: CPEX Pharmaceuticals Inc.
Trial primary completion date: Feb 2016 --> Dec 2016 N=16 --> 0
- Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment change, Trial initiation date: Evaluate Safety of Technosphere (clinicaltrials.gov) - Feb 16, 2016
P3, N=34, Terminated, Sponsor: Sanofi
N=16 --> 0 N=24 --> 34 | Initiation date: Jun 2008 --> Mar 2009
- Trial completion, Enrollment change, Trial primary completion date: Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study (clinicaltrials.gov) - Feb 16, 2016
P1, N=10, Completed, Sponsor: University of Pittsburgh
N=24 --> 34 | Initiation date: Jun 2008 --> Mar 2009 Active, not recruiting --> Completed | N=15 --> 10 | Trial primary completion date: Dec 2010 --> Jan 2012
- teriflunomide / Generic mfg.
Trial completion, Trial primary completion date: Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months (clinicaltrials.gov) - Feb 13, 2016
P=N/A, N=50, Completed, Sponsor: University at Buffalo
Active, not recruiting --> Completed | N=15 --> 10 | Trial primary completion date: Dec 2010 --> Jan 2012 Recruiting --> Completed | Trial primary completion date: Nov 2014 --> Oct 2015
- Avonex (recombinant IFN-β-1a) / Biogen
Trial completion: Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study (clinicaltrials.gov) - Feb 13, 2016
P=N/A, N=159, Completed, Sponsor: University at Buffalo
Recruiting --> Completed | Trial primary completion date: Nov 2014 --> Oct 2015 Active, not recruiting --> Completed
- | Enbrel (etanercept) / Pfizer, Amgen
Enrollment open: TARGET-DLE: Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus (clinicaltrials.gov) - Feb 12, 2016
P2, N=25, Recruiting, Sponsor: University of Leeds
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Rebif (human IFN-β-1a) / EMD Serono
Trial primary completion date: RELIEF: A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Feb 12, 2016
P4, N=218, Recruiting, Sponsor: Merck KGaA
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2015 --> Apr 2016